BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17869098)

  • 1. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new Hsp90 inhibitors by structure-based virtual screening.
    Hong TJ; Park H; Kim YJ; Jeong JH; Hahn JS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4839-42. PubMed ID: 19560353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
    Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
    Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors.
    Thorat DA; Doddareddy MR; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1593-7. PubMed ID: 21353544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
    Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.
    Huang KH; Barta TE; Rice JW; Smith ED; Ommen AJ; Ma W; Veal JM; Fadden RP; Barabasz AF; Foley BE; Hughes PF; Hanson GJ; Markworth CJ; Silinski M; Partridge JM; Steed PM; Hall SE
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2550-4. PubMed ID: 22386527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.
    Cheung KM; Matthews TP; James K; Rowlands MG; Boxall KJ; Sharp SY; Maloney A; Roe SM; Prodromou C; Pearl LH; Aherne GW; McDonald E; Workman P
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3338-43. PubMed ID: 15955698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.
    Park H; Li M; Choi J; Cho H; Ham SW
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4372-5. PubMed ID: 19500977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based identification of Hsp90 inhibitors.
    Barker JJ; Barker O; Boggio R; Chauhan V; Cheng RK; Corden V; Courtney SM; Edwards N; Falque VM; Fusar F; Gardiner M; Hamelin EM; Hesterkamp T; Ichihara O; Jones RS; Mather O; Mercurio C; Minucci S; Montalbetti CA; Müller A; Patel D; Phillips BG; Varasi M; Whittaker M; Winkler D; Yarnold CJ
    ChemMedChem; 2009 Jun; 4(6):963-6. PubMed ID: 19301319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of a new class of Hsp90 inhibitors.
    Barril X; Brough P; Drysdale M; Hubbard RE; Massey A; Surgenor A; Wright L
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5187-91. PubMed ID: 16202589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.